Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Clofarabine. Bioenvision/ILEX.

Alexander Sternberg¹

¹Academic Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK. stern@molbiol.ox.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)

|February 7, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).

British journal of haematology·2022

Same author

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

The Journal of experimental medicine·2016

Same author

Guidelines for the diagnosis and management of adult myelodysplastic syndromes.

British journal of haematology·2013

Same author

Hypereosinophilic syndrome masquerading as a myocardial infarction causing decompensated heart failure.

BMC cardiovascular disorders·2013

Same author

Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma.

British journal of haematology·2013

Same author

Meningeal myelomatosis.

Blood·2012

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Clofarabine, a novel antimetabolite, is being investigated for various cancers. Clinical trials are underway for pediatric acute lymphoblastic leukemia and acute leukemia in children.

Area of Science:

Oncology
Pharmacology

Background:

Clofarabine is a purine nucleoside antimetabolite.
It is under development for treating solid tumors and various leukemias.

Purpose of the Study:

To evaluate clofarabine's potential in treating acute myelogenous leukemia, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.
To assess clofarabine's efficacy in pediatric acute lymphoblastic leukemia.

Main Methods:

Phase II clinical trial initiated in Europe for pediatric acute lymphoblastic leukemia.
Submission of a rolling New Drug Application (NDA) to the FDA for treating acute leukemia in children.

Main Results:

Ongoing clinical development and regulatory submissions indicate promising therapeutic potential.

Related Experiment Videos

Conclusions:

Clofarabine shows promise as a treatment for various hematological malignancies, particularly in pediatric populations.
Further clinical evaluation and regulatory review are in progress.